NKTR Nektar Therapeutics
- 1.7380
- +0.1380+8.63%
Nektar Therapeutics News
Q1 2024 Nektar Therapeutics Earnings Call
Earnings Call Summary | Nektar Therapeutics(NKTR.US) Q1 2024 Earnings Conference
The following is a summary of the Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript:Financial Performance:Nektar ended Q1 with a cash balance of $326 million and anticipates to close 2
Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript
Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript
Nektar Therapeutics Q1 2024 GAAP EPS $(0.19) Beats $(0.20) Estimate, Sales $21.639M Beat $15.342M Estimate
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 73.97 percent increase over losses of $(0.
Nektar Therapeutics Q1 Loss Drops In Line With Estimates
Nektar Therapeutics 1Q Rev $21.6M >NKTR
Nektar Therapeutics 1Q Rev $21.6M >NKTR
Press Release: Nektar Therapeutics Reports First Quarter 2024 Financial Results
Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire SAN FRANCISCO, May 9, 2024 SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported
Nektar Therapeutics Reports First Quarter 2024 Financial Results
SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securi
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based fin
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersCyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shar
NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)
Nektar Therapeutics Receives Letter That It Has Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq Capital Market - Filing
To regain compliance with the Minimum Bid Price Requirement, the Company's common stock was required to maintain a closing bid price of $1.00 per share or greater for at least 10 consecutive business
NKTR, VERU and EGIO Among Mid-day Movers
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Nektar Therapeutics Is Worried About This – Should You Be Worried Too?
Nektar Therapeutics Is Maintained at Hold by Jefferies
Nektar Therapeutics Is Maintained at Hold by Jefferies
Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1
Jefferies analyst Roger Song maintains Nektar Therapeutics (NASDAQ:NKTR) with a Hold and raises the price target from $0.5 to $1.
Nektar Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/06/2024 13.64% Jefferies $0.5 → $1 Maintains Hold 11/20/2023 — JP Morgan Reinstates → Underweight 11/0
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata
Nektar Therapeutics (NKTR) said Tuesday it started the phase 2b trial for rezpegaldesleukin to treat patients experiencing severe to very severe alopecia areata. The Phase 2b study will evaluate rezpe
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating.
Analysis
Price Target
No Data
